IN VITRO INHIBITION OF UDP GLUCURONOSYLTRANSFERASES BY ATAZANAVIR AND OTHER HIV PROTEASE INHIBITORS AND THE RELATIONSHIP OF THIS PROPERTY TO IN VIVO BILIRUBIN GLUCURONIDATION

Human UDP-Glucuronosyltransferases: Metabolism, Expression, and Disease

Tukey, R. H., & Strassburg, C. P. (2000) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.40.1.581 · Cited by 1,523

DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS

Williams, J. A., Hyland, R., Jones, B. C., Smith, D. A., Hurst, S., Goosen, T. C., Peterkin, V., Koup, J. R., & Ball, S. E. (2004) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.000794 · Cited by 928

IN VITRO AND IN VIVO DRUG INTERACTIONS INVOLVING HUMAN CYP3A

Thummel, K. E., & Wilkinson, G. R. (1998) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.38.1.389 · Cited by 831

Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions

Bertz, R. J., & Granneman, G. R. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199732030-00004 · Cited by 755

UDP-glucuronosyltransferases and clinical drug-drug interactions

KIANG, T., ENSOM, M., & CHANG, T. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.10.013 · Cited by 552

Metabolic Control and Disease.

(1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-92-6-887_2 · Cited by 541

Prediction of Pharmacokinetic Alterations Caused by Drug-Drug Interactions: Metabolic Interaction in the Liver

Ito, K., Iwatsubo, T., Kanamitsu, S., Ueda, K., Suzuki, H., & Sugiyama, Y. (1998) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01372-3 · Cited by 512

Annual Review of Pharmacology,

Williams, J. F. (1975) · Archives of Internal Medicine · doi:10.1001/archinte.1975.00330100136032 · Cited by 386

The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism*†

Fisher, M. B., Paine, M. F., Strelevitz, T. J., & Wrighton, S. A. (2001) · Drug Metabolism Reviews · doi:10.1081/dmr-120000653 · Cited by 375

Human Drug Metabolism and the Cytochromes P450: Application and Relevance of In Vitro Models

Venkatakrishnan, K., von Moltke, L. L., & Greenblatt, D. J. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122012724 · Cited by 308

Database analyses for the prediction of in vivo drug–drug interactions from in vitro data

Ito, K., Brown, H. S., & Houston, J. B. (2004) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2003.02041.x · Cited by 272

Mechanism of indinavir-induced hyperbilirubinemia

Zucker, S. D., Qin, X., Rouster, S. D., Yu, F., Green, R. M., Keshavan, P., Feinberg, J., & Sherman, K. E. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.231140698 · Cited by 262

Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3.

Green, M. D., King, C. D., Mojarrabi, B., Mackenzie, P. I., & Tephly, T. R. (1998) · PubMed · Cited by 253

Mechanism-Based Inactivation of CYP3A by HIV Protease Inhibitors

Ernest, C. S., Hall, S. D., & Jones, D. R. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.075416 · Cited by 246

Hepatic Secretion of Conjugated Drugs and Endogenous Substances

KEPPLER, D., & KÖNIG, J. (2000) · Seminars in Liver Disease · doi:10.1055/s-2000-9391 · Cited by 245

Investigation of the substrate specificity of a cloned expressed human bilirubin UDP-glucuronosyltransferase: UDP-sugar specificity and involvement in steroid and xenobiotic glucuronidation

Senafi, S. B., Clarke, D. J., & Burchell, B. (1994) · Biochemical Journal · doi:10.1042/bj3030233 · Cited by 238

Specificity of human UDP-Glucuronosyltransferases and xenobiotic glucuronidation

Burchell, B., Brierley, C. H., & Rance, D. (1995) · Life Sciences · doi:10.1016/0024-3205(95)02073-r · Cited by 224

Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance

Miners, J. O., McKinnon, R. A., & Mackenzie, P. I. (2002) · Toxicology · doi:10.1016/s0300-483x(02)00449-3 · Cited by 210

Predicting Human Drug Glucuronidation Parameters: Application of In Vitro and In Silico Modeling Approaches

Miners, J. O., Smith, P. A., Sorich, M. J., McKinnon, R. A., & Mackenzie, P. I. (2004) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121546 · Cited by 210

Kinetics of drug-drug interactions

Rowland, M., & Matin, S. B. (1973) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059791 · Cited by 208

Drug-Induced Liver Injury Associated with Antiretroviral Therapy that Includes HIV-1 Protease Inhibitors

Sulkowski, M. S. (2004) · Clinical Infectious Diseases · doi:10.1086/381444 · Cited by 192

Drug-Drug Interactions

Huang, S.-M. (2004) · Applications of Pharmacokinetic Principles in Drug Development · doi:10.1007/978-1-4419-9216-1_10 · Cited by 181

GLUCURONIDATION OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS: IDENTIFYING THE ENZYMES RESPONSIBLE IN HUMAN LIVER MICROSOMES

Kuehl, G. E., Lampe, J. W., Potter, J. D., & Bigler, J. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.002527 · Cited by 177

Drug Glucuronidation in Clinical Psychopharmacology

Liston, H. L., Markowitz, J. S., & DeVane, C. L. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200110000-00008 · Cited by 177

Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin

BRIZ, O., SERRANO, M. A., MACIAS, R. I. R., GONZALEZ-GALLEGO, J., & MARIN, J. J. G. (2003) · Biochemical Journal · doi:10.1042/bj20030034 · Cited by 175

Recent advances in bilirubin metabolism research: the molecular mechanism of hepatocyte bilirubin transport and its clinical relevance

Kamisako, T., Kobayashi, Y., Takeuchi, K., Ishihara, T., Higuchi, K., Tanaka, Y., Gabazza, E. C., & Adachi, Y. (2000) · Journal of Gastroenterology · doi:10.1007/s005350070044 · Cited by 160

CYP3A4 Substrate Selection and Substitution in the Prediction of Potential Drug-Drug Interactions

Galetin, A., Ito, K., Hallifax, D., & Houston, J. B. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.082826 · Cited by 158

Drug Interactions Between Antiretroviral Drugs and Comedicated Agents

de Maat, M. M. R., Ekhart, G. C., Huitema, A. D. R., Koks, C. H. W., Mulder, J. W., & Beijnen, J. H. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342030-00002 · Cited by 150

IMPACT OF PARALLEL PATHWAYS OF DRUG ELIMINATION AND MULTIPLE CYTOCHROME P450 INVOLVEMENT ON DRUG-DRUG INTERACTIONS: CYP2D6 PARADIGM

Ito, K., Hallifax, D., Obach, R. S., & Houston, J. B. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.003715 · Cited by 149

Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia

Campbell, S. D., de Morais, S. M., & Xu, J. J. (2004) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2004.08.008 · Cited by 144

Impact of Nonspecific Binding to Microsomes and Phospholipid on the Inhibition of Cytochrome P4502D6: Implications for Relating in Vitro Inhibition Data to in Vivo Drug Interactions

Margolis, J. M., & Obach, R. S. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.5.606 · Cited by 135

In vitro–in vivo correlations for drugs eliminated by glucuronidation: Investigations with the model substrate zidovudine

Boase, S., & Miners, J. O. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01669.x · Cited by 120

Role of MRP4 and MRP5 in biology and chemotherapy

Sampath, J., Adachi, M., Hatse, S., Naesens, L. M. J., Balzarini, J. M., Flatley, R. M., Matherly, L. H., & Schuetz, J. D. (2002) · AAPS PharmSci · doi:10.1208/ps040314 · Cited by 117

KINETIC CHARACTERIZATION OF THE 1A SUBFAMILY OF RECOMBINANT HUMAN UDP-GLUCURONOSYLTRANSFERASES

Luukkanen, L., Taskinen, J., Kurkela, M. J., Kostiainen, R. K., Hirvonen, J. J., & Finel, M. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.105.004093 · Cited by 100

Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in humans.

Balani, S. K., Woolf, E., Hoagland, V. D., Sturgill, M. G., Deutsch, P., Yeh, K. C., & Lin, J. H. (1996) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08479-x · Cited by 96

Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data?

Ito, K., Chiba, K., Horikawa, M., Ishigami, M., Mizuno, N., Aoki, J., Gotoh, Y., Iwatsubo, T., Kanamitsu, S.-I., Kato, M., et al. (2002) · AAPS PharmSci · doi:10.1208/ps040425 · Cited by 86

Inhibition‐Based Metabolic Drug–Drug Interactions: Predictions from In Vitro Data

Yao, C., & Levy, R. H. (2002) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10179 · Cited by 74

Bile pigments as HIV-1 protease inhibitors and their effects on HIV-1 viral maturation and infectivity in vitro

McPhee, F., Caldera, P., Bemis, G. W., McDonagh, A. F., Kuntz, I. D., & Craik, C. S. (1996) · Biochemical Journal · doi:10.1042/bj3200681 · Cited by 64

Human UDP‐glucuronosyl transferases: Chemical defence, jaundice and gene therapy

Brierley, C. H., & Burchell, B. (1993) · BioEssays · doi:10.1002/bies.950151108 · Cited by 57

ACYL GLUCURONIDATION OF FLUOROQUINOLONE ANTIBIOTICS BY THE UDP-GLUCURONOSYLTRANSFERASE 1A SUBFAMILY IN HUMAN LIVER MICROSOMES

Tachibana, M., Tanaka, M., Masubuchi, Y., & Horie, T. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.003178 · Cited by 51

Inhibition and Active Sites of UDP-Glucuronosyltransferases 2B7 and 1A1.

Rios, G. R., & Tephly, T. R. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.12.1364 · Cited by 48

Use of In Vitro Drug Metabolism Data to Evaluate Metabolic Drug‐Drug Interactions in Man: The Need for Quantitative Databases

Rodrigues, A. D., Winchell, G. A., & Dobrinska, M. R. (2001) · The Journal of Clinical Pharmacology · doi:10.1177/00912700122010212 · Cited by 45

Hepatic microsomal glucuronidation of bilirubin is modulated by the lipid microenvironment of membrane-bound substrate.

Whitmer, D. I., Russell, P. E., Ziurys, J. C., et al. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)38370-9 · Cited by 14

Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates

Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.013 · Cited by 835

Hyperbilirubinemia syndromes (Gilbert-Meulengracht, Crigler-Najjar, Dubin-Johnson, and Rotor syndrome)

Strassburg, C. P. (2010) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2010.07.007 · Cited by 184